The potential of insulin-like growth factor-I as a therapeutic for the treatment of neuromuscular disorders.
Lewis
M E
ME
Cephalon, Inc., West Chester, Pennsylvania 19380.
Vaught
J L
JL
Neff
N T
NT
Grebow
P E
PE
Callison
K V
KV
Yu
E
E
Contreras
P C
PC
Baldino
F
F
D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy; D000818:Animals; D016923:Cell Death / Q000187:drug effects; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D009409:Nerve Crush; D009468:Neuromuscular Diseases / Q000188:drug therapy*; D009474:Neurons / Q000166:cytology / Q000187:drug effects; D010525:Peripheral Nerves / Q000166:cytology / Q000187:drug effects / Q000502:physiology; D010523:Peripheral Nervous System Diseases / Q000188:drug therapy; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D013116:Spinal Cord / Q000166:cytology / Q000187:drug effects / Q000378:metabolism
D011994:Recombinant Proteins; D007334:Insulin-Like Growth Factor I